Essay Available:
Pages:
1 page/β275 words
Sources:
No Sources
Style:
APA
Subject:
Education
Type:
Other (Not Listed)
Language:
English (U.S.)
Document:
MS Word
Date:
Total cost:
$ 3.96
Topic:
Patents search
Other (Not Listed) Instructions:
Jonathan Spadt's presentation on intellectual property was focused on the drug Solabegron (http://en(dot)wikipedia(dot)org/wiki/Solabegron ), which is a beta-3-adrenoceptor compound. In order to develop some additional background on searching for and understanding patents, please prepare a short write-up (bullet item lists are fine) in which you:
1--Identify the original 2 patents on beta-3-adrenoceptors that were assigned to Glaxo (the company name was Glaxo Wellcome at that time). When were these filed and when were they actually approved?
2--The Claims actually define what is covered by the patent. How many claims are there in the 2001 Glaxo patent? Read through the Claims and provide a brief summary.
3--What is "novel" in the 2001 Glaxo patent according to the inventors?
4--Identify all subsequent patents that reference the 2001 Glaxo patent. What companies filed these patents?
There are a number of different web resources for searching patents. The ones I recommend are: www(dot)uspto(dot)gov (this is the official US government site) and www(dot)google(dot)com/patents. There is also information available on patent searching through the Penn State libraries at http://www(dot)libraries(dot)psu(dot)edu/psul/pams/patent.html.
Other (Not Listed) Sample Content Preview:
Running head: Patents search
Patents on beta-3-adrenoceptors
Name:
Subject:
College:
Instructor:
Date
Introduction
Beta-3-adrenoceptors also referred to as Atypical beta-adrenoceptors is a chemical compound initially believed to treat conditions such as type 2 diabetes, preterm labor, obesity, , heart failure depressions and anxiety. This compound has undergone a number of filed patent petitions by different companies and incorporations in the United States among other nations. This brief description therefore identifies some of the initial patents on beta-3-adrenoceptor to be filed and accepted by the United States Patent and Trademark Office.
The first Patent to be filed and issued upon acceptance by the US government with respect to this chemical was presented by Glaxo Inc. back in the year 1998. The first patent with patent number: 6048872 were filed on the 5th of June, 1998. This patent was fully approved on the 11th of April 2000. This patent was granted based on the arguments that this chemical compound had the capacity to treat any human or even non-human victim of any gastrointestinal related disease such as gastritis, oesophagitis, or duodenitis, whereby an effective and substantial amount of this compound would be administered to the subject therefore acting as an agonist at and considered being atypical beta-adrenoceptors selective.
With respect to the Beta-3 Adrenoceptor Patent application by the Glaxo Inc. in 2001(WO/2001/042217) a number of claims are identified that earns it the approval from United States Patent and Trademark Office. Below is a summary of such claims.
...
Patents on beta-3-adrenoceptors
Name:
Subject:
College:
Instructor:
Date
Introduction
Beta-3-adrenoceptors also referred to as Atypical beta-adrenoceptors is a chemical compound initially believed to treat conditions such as type 2 diabetes, preterm labor, obesity, , heart failure depressions and anxiety. This compound has undergone a number of filed patent petitions by different companies and incorporations in the United States among other nations. This brief description therefore identifies some of the initial patents on beta-3-adrenoceptor to be filed and accepted by the United States Patent and Trademark Office.
The first Patent to be filed and issued upon acceptance by the US government with respect to this chemical was presented by Glaxo Inc. back in the year 1998. The first patent with patent number: 6048872 were filed on the 5th of June, 1998. This patent was fully approved on the 11th of April 2000. This patent was granted based on the arguments that this chemical compound had the capacity to treat any human or even non-human victim of any gastrointestinal related disease such as gastritis, oesophagitis, or duodenitis, whereby an effective and substantial amount of this compound would be administered to the subject therefore acting as an agonist at and considered being atypical beta-adrenoceptors selective.
With respect to the Beta-3 Adrenoceptor Patent application by the Glaxo Inc. in 2001(WO/2001/042217) a number of claims are identified that earns it the approval from United States Patent and Trademark Office. Below is a summary of such claims.
...
Get the Whole Paper!
Not exactly what you need?
Do you need a custom essay? Order right now:
π Other Visitors are Viewing These APA Other (Not Listed) Samples:
- Past and present education 1 page/β275 words | No Sources | APA | Education | Other (Not Listed) |
- Review of literature related to the field of learning environments5 pages/β1375 words | 1 Source | APA | Education | Other (Not Listed) |
- Statement of Purpose: humble why i want to study master of teaching primary1 page/β275 words | No Sources | APA | Education | Other (Not Listed) |
- SPED 400/500 Personal Philosophy Paper: Attention Deficit Disorder3 pages/β825 words | 4 Sources | APA | Education | Other (Not Listed) |
- Concrete-polymer composites (Materials)4 pages/β1100 words | No Sources | APA | Education | Other (Not Listed) |
- Handbook Family reading project1 page/β275 words | 1 Source | APA | Education | Other (Not Listed) |
- Ebooks vs old school5 pages/β1375 words | 5 Sources | APA | Education | Other (Not Listed) |